524-P: CME Activity Series Highlights Changes in Clinicians’ Knowledge and Competence about Novel Approaches to Reduce DKD Progression

Abstract

Diabetic kidney disease (DKD) is one of the most common complications of diabetes, significantly impacting morbidity and mortality. Novel approaches to target DKD progression are needed, and non-steroidal mineralocorticoid receptor antagonists (MRAs) have recently emerged as a viable option, however, clinicians may not be aware of them. Based on this gap, CMHC organized 4 accredited virtual symposia from 2020 to 2021 to educate multi-disciplinary clinicians and assess knowledge/competence changes using pre-/post assessment questions. The activities took place between Oct. 2020 - Oct 2021 with the participation of 829 healthcare professionals (MD/DO, PAs, RNs, NPs, PharmDs) representing specialties that treat high-risk diabetes patients. A Chi-Square test was used to analyze the percentage of correct responses and determine statistical significance (p <0.05) . A significant increase in knowledge regarding the pathophysiology of DKD and emerging non-steroidal MRAs in DKD was observed (43% and 34% relative increase in knowledge compared to baseline, p <0.0001) . Additionally, a significant increase in competency regarding identifying patients at-risk for DKD progression and management of DKD patients was demonstrated (37% relative increased to baseline, p<0.0001) . At post-activity evaluation, 99.7% indicated that information via these activities is useful for their practice. Furthermore, the majority of participants indicated that they intended to change their practice based on information received, including monitoring clinical trial advances with non-steroidal MRAs, evaluating the risk of potential hyperkalemia with DKD treatments, and screen for risk of DKD progression. It is evident from the outcomes of these educational activities that they led to significant improvement in knowledge and competence related to novel DKD treatment options and commitment to change among learners. Disclosure S.Karandrea: None. N.Agarwal: None. A.Jamrogiewicz: None. Funding Bayer HealthCare Pharmaceuticals (24656) Bayer HealthCare Pharmaceuticals (66351473) Bayer HealthCare Pharmaceuticals (25319) Bayer HealthCare Pharmaceuticals (67463661)